Go Deep
Tri Chemical Laboratories Inc.
Tri Chemical Laboratories Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,724 | 15.9 | 2.54 | 0.15 | 1,811.25 |
| Oct 2026 | 21,946 | 15.4 | 2.56 | 0.15 | 1,818.66 |
Tri Chemical Laboratories Inc. Quarterly Results
| Line Item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 |
|---|---|---|---|---|
| Revenue | 7,217,200,000.0 | 7,488,666,000.0 | 5,872,755,000.0 | 5,635,261,000.0 |
| Net Profit | 1,518,178,000.0 | 1,855,377,000.0 | 1,493,561,000.0 | 1,244,768,000.0 |
| EPS | — | 57.1 | — | — |
Tri Chemical Laboratories Inc. Revenue & Profit: Last 5 Years
| Line Item | Jan 2026 | Jan 2025 | Jan 2024 | Jan 2023 | Jan 2022 |
|---|---|---|---|---|---|
| Revenue | 23,883,175,000.0 | 18,905,888,000.0 | 11,246,293,000.0 | 13,803,392,000.0 | — |
| Net Profit | 5,515,240,000.0 | 4,961,998,000.0 | 2,470,625,000.0 | 4,832,417,000.0 | — |
| EPS | 169.7 | 152.7 | 76.0 | 148.7 | — |
Tri Chemical Laboratories Inc. Balance Sheet
| Line Item | Jan 2026 | Jan 2025 | Jan 2024 | Jan 2023 | Jan 2022 |
|---|---|---|---|---|---|
| Total Assets | 47,274,965,000.0 | 36,944,588,000.0 | 31,864,933,000.0 | 32,115,559,000.0 | — |
| Total Liabilities | 11,125,415,000.0 | 5,356,905,000.0 | 4,294,519,000.0 | 6,239,500,000.0 | — |
| Total Equity | 36,149,550,000.0 | 31,587,683,000.0 | 27,570,414,000.0 | 25,876,059,000.0 | — |
Owes vs Owns
Tri Chemical Laboratories Inc. owed ¥0.22 for every ¥1 it owned in Jul 2026, up from ¥0.19 in Jan 2023.
| Period | Jul 2026 | Jan 2026 | Jan 2025 | Jan 2024 | Jan 2023 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.22× | 0.24× | 0.14× | 0.13× | 0.19× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Tri Chemical Laboratories Inc. Assets & Liabilities Breakdown (JPY millions)
What it owns — Jan 2026
Cash & short-term investments 15.4%Receivables 9.4%Inventory 16.6%Fixed assets (tangible) 36.4%Long-term investments 13.0%Other assets 9.0%
How it's funded — Jan 2026
Short-term debt 1.4%Long-term debt 6.5%Payables 4.3%Other liabilities 11.3%Shareholders' equity 76.5%
| Line Item | Jan 2026 | Jan 2025 | Jan 2024 | Jan 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 7,280.0 | 9,439.3 | 10,497.3 | 11,137.8 |
| Receivables | 4,441.0 | 3,627.2 | 2,687.3 | 3,504.8 |
| Inventory | 7,865.9 | 5,976.0 | 4,022.9 | 2,740.0 |
| Fixed assets (tangible) | 17,225.3 | 10,936.3 | 9,269.2 | 8,372.7 |
| Intangible assets | 89.6 | 74.2 | 105.4 | 134.8 |
| Long-term investments | 6,139.6 | 3,923.2 | 2,977.5 | 4,400.4 |
| Other assets | 4,233.5 | 2,968.3 | 2,305.2 | 1,825.0 |
| Liabilities & equity | ||||
| Short-term debt | 640.2 | 653.1 | 700.9 | 785.4 |
| Long-term debt | 3,082.8 | 723.0 | 1,212.9 | 1,913.8 |
| Payables | 2,045.6 | 969.8 | 354.4 | 1,142.1 |
| Other liabilities | 5,356.9 | 3,011.0 | 2,026.3 | 2,398.2 |
| Shareholders' equity | 36,149.6 | 31,587.7 | 27,570.4 | 25,876.1 |
| Net tangible assets | 36,060.0 | 31,513.4 | 27,465.0 | 25,741.3 |
Tri Chemical Laboratories Inc. Cash Flow
| Line Item | Jan 2026 | Jan 2025 | Jan 2024 | Jan 2023 | Jan 2022 |
|---|---|---|---|---|---|
| Operating Activities | 3,795,166,000.0 | 3,675,110,000.0 | 2,972,015,000.0 | 6,392,057,000.0 | — |
| Investing Activities | -7,054,145,000.0 | -3,116,065,000.0 | -1,781,833,000.0 | -1,557,570,000.0 | — |
| Financing Activities | 1,088,296,000.0 | -1,620,462,000.0 | -1,858,875,000.0 | -1,703,583,000.0 | — |